Literature DB >> 28477316

Gestational choriocarcinoma associated with a germline TP53 mutation.

Anne-Claire Brehin1,2, Sophie Patrier-Sallebert1, Gaëlle Bougeard2, Gwendoline Side-Pfennig1, Francisco Llamas Gutierrez3, Aude Lamy1, Elodie Colasse1, Christine Kandel-Aznar4, Capucine Delnatte5, Eric Vuillemin6, Sophie Sadot-Lebouvier7, Sylvie Odent8, Jean-Christophe Sabourin1, François Golfier9, Thierry Frebourg10.   

Abstract

Choriocarcinoma is a highly malignant neoplasm resulting from the malignant transformation of proliferating trophoblastic cells and the molecular mechanisms leading to this transformation remain to be characterized. We report here the first case of a female germline TP53 mutation carrier who developed, as a first tumour, a lung choriocarcinoma, 6 months after a normal delivery. Molecular analyses established the gestational origin of the choriocarcinoma and showed, within the tumour, the presence of the germline mutant TP53 allele and loss of the wild-type allele. Resistance to methotrexate chemotherapy led to perform a surgical resection of the tumour. In agreement with the permissive role of TP53 mutations to oncogenic events, this report strongly suggests that TP53 mutations may promote malignant transformation of proliferating trophoblastic cells. Therefore, female TP53 mutation carriers may have an increased risk of developing gestational choriocarcinoma and might benefit from β-hCG level monitoring after pregnancy.

Entities:  

Keywords:  Choriocarcinoma; Gestational choriocarcinoma; Gestational trophoblastic disease; Li-Fraumeni syndrome; TP53

Mesh:

Substances:

Year:  2018        PMID: 28477316     DOI: 10.1007/s10689-017-9996-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  10 in total

1.  Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M J Seckl; N J Sebire; R A Fisher; F Golfier; L Massuger; C Sessa
Journal:  Ann Oncol       Date:  2013-09-01       Impact factor: 32.976

2.  Transmission of germline TP53 mutations from male carriers to female partners.

Authors:  Sophie Patrier-Sallebert; Gaëlle Bougeard; Stéphanie Baert-Desurmont; Aude Lamy; Jean-Michel Flaman; Ludovic Mansuy; Myriam Bronner; Christine Lasset; Laurence Brugières; François Golfier; Thierry Frebourg
Journal:  J Med Genet       Date:  2015-01-22       Impact factor: 6.318

3.  A case of primary pulmonary choriocarcinoma successfully treated by surgery.

Authors:  Satoshi Kamata; Akira Sakurada; Nobuyuki Sato; Masafumi Noda; Yoshinori Okada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-28

4.  Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.

Authors:  D Malkin; K W Jolly; N Barbier; A T Look; S H Friend; M C Gebhardt; T I Andersen; A L Børresen; F P Li; J Garber
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

5.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Authors:  Gaëlle Bougeard; Mariette Renaux-Petel; Jean-Michel Flaman; Camille Charbonnier; Pierre Fermey; Muriel Belotti; Marion Gauthier-Villars; Dominique Stoppa-Lyonnet; Emilie Consolino; Laurence Brugières; Olivier Caron; Patrick R Benusiglio; Brigitte Bressac-de Paillerets; Valérie Bonadona; Catherine Bonaïti-Pellié; Julie Tinat; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

6.  Molecular genetic analyses of choriocarcinoma.

Authors:  J Zhao; Y Xiang; X R Wan; F Z Feng; Q C Cui; X Y Yang
Journal:  Placenta       Date:  2009-07-31       Impact factor: 3.481

7.  Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015).

Authors:  C Tempfer; L-C Horn; S Ackermann; M W Beckmann; R Dittrich; J Einenkel; A Günthert; H Haase; J Kratzsch; M C Kreissl; S Polterauer; A D Ebert; K T M Schneider; H G Strauss; F Thiel
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

8.  The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies.

Authors:  Rosemary A Fisher; Philip M Savage; Caitriona MacDermott; Jane Hook; Neil J Sebire; Iain Lindsay; Michael J Seckl
Journal:  Gynecol Oncol       Date:  2007-10-22       Impact factor: 5.482

Review 9.  Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.

Authors:  Junne Kamihara; Huma Q Rana; Judy E Garber
Journal:  Hum Mutat       Date:  2014-06       Impact factor: 4.878

10.  Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours.

Authors:  Y F Shi; X Xie; C L Zhao; D F Ye; S M Lu; J J Hor; C C Pao
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  10 in total
  3 in total

1.  Report of a bi-allelic truncating germline mutation in TP53.

Authors:  Natasha J Brown; Kanika Bhatia; Julie Teague; Susan M White; Patrick Lo; Jackie Challis; Victoria Beshay; Michael Sullivan; David Malkin; Jordan R Hansford
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

2.  Targeted Delivery Prodigiosin to Choriocarcinoma by Peptide-Guided Dendrigraft Poly-l-lysines Nanoparticles.

Authors:  Kai Zhao; Dan Li; Guogang Cheng; Baozhen Zhang; Jinyu Han; Jie Chen; Baobei Wang; Mengxia Li; Tianxia Xiao; Jian Zhang; Dongpo Zhou; Zheng Jin; Xiujun Fan
Journal:  Int J Mol Sci       Date:  2019-11-01       Impact factor: 5.923

Review 3.  Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner.

Authors:  Jennifer A Cotter; Linda Szymanski; Catherine Karimov; Lara Boghossian; Ashley Margol; Girish Dhall; Benita Tamrazi; G Isaac Varaprasathan; David M Parham; Alexander R Judkins; Jaclyn A Biegel
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.